Radiation nanomedicine is a term that our group first used in 2015 to describe gold nanoparticles (AuNPs) conjugated to the anti-epidermal growth factor receptor (EGFR) monoclonal antibody panitumumab (Vectibix®, Amgen) and labeled with β-particle emitting, 177Lu for local treatment of EGFR-positive breast cancer (BC) (Yook et al. 2015). This evidence concerns the gene EGFR and breast carcinoma.